Regeneron Pharmaceuticals, Inc.
REGNRegeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Drugs in Pipeline
113
Phase 3 Programs
62
Upcoming Catalysts
32
Next Catalyst
Jul 30, 2026
TomorrowMarket Overview
Stock performance and key metrics
32 upcoming, 8 past
REGN Earnings Report
EPS Est: $8.00 | FQ end 2026-06 | Call: 2026-07-30 15:00:00
31 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How REGN's past catalysts played out
Dupixent
Dupilumab
Atopic Dermatitis
aflibercept 8 mg PFS
Diabetic Macular Edema (DME)
Cemdisiran
Paroxysmal Nocturnal Hemoglobinuria
Investigator Choice (IC) Chemotherapy
Squamous Cell Carcinoma (SCC)
Rilonacept
Gout
Suptavumab 30 mg/kg
Respiratory Syncytial Virus Infections
cemiplimab
Advanced Cutaneous Squamous Cell Carcinoma
Elotuzumab
Relapsed Refractory Multiple Myeloma (RRMM)
Garetosmab
Fibrodysplasia Ossificans Progressiva
Statin
Hypercholesterolemia
Fasinumab
Osteoarthritis of the Knee or Hip
REGN5715
Allergic Conjunctivitis
Lenalidomide
Relapsed/Refractory Follicular Lymphoma
Pembrolizumab
Melanoma
Evinacumab
Hypercholesterolemia
Linvoseltamab
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Atorvastatin
Hypercholesterolemia
Naproxen
Osteoarthritis, Knee
Doxorubicin
Follicular Lymphoma (FL)
Carfilzomib
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Ravulizumab
Paroxysmal Nocturnal Hemoglobinuria
Fianlimab
Melanoma
rilonacept 160 mg
Familial Cold Autoinflammatory Syndrome (FCAS)
REGN5714
Allergic Rhinitis
VEGF Trap-Eye 2.0mg
Macular Edema Secondary to Central Retinal Vein Occlusion
Daratumumab
High Risk Smoldering Multiple Myeloma (HR-SMM)
Pozelimab + Cemdisiran
Generalized Myasthenia Gravis
Pozelimab
CD55-deficient Protein-losing Enteropathy
ranibizumab
Macular Degeneration
Pemetrexed
Non-small Cell Lung Cancer
mibavademab
Generalized Lipodystrophy
REGN9933
Venous Thromboembolism
Oral corticosteroids (OCS)
Bullous Pemphigoid
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
Diabetic Macular Edema
REGN1908
Allergic Conjunctivitis
Rosuvastatin
Hypercholesterolemia
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Branch Retinal Vein Occlusion
Acetylsalicylic Acid (ASA)
Symptomatic Venous Thromboembolism (VTE)
Rilonacept 80 mg
Intercritical Gout
Aflibercept 8 mg
Neovascular Age-Related Macular Degeneration
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Macular Degeneration
REGN7508
Venous Thromboembolism (VTE)
Libtayo
Cemiplimab
Non-Small Cell Lung Cancer
Alirocumab
Homozygous Familial Hypercholesterolemia
Intravitreal Aflibercept Injection 2mg
Neovascular Age-related Macular Degeneration
Rivaroxaban
Peripheral Artery Disease (PAD)
Apixaban
Atrial Fibrillation (AF)
Sarilumab
COVID-19
Ezetimibe
Hypercholesterolemia
REGN475
Sciatica
REGN2810
Non-small Cell Lung Cancer
Carboplatin
Resectable Non-small Cell Lung Cancer
REGN10933 + REGN10987
Healthy Participants
Gemcitabine
Carcinoma，Non-Small-Cell Lung
LMT (atorvastatin, simvastatin, or rosuvastatin)
Heterozygous Familial Hypercholesterolemia
Dexamethasone
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Dupilumab
Atopic Dermatitis (AD)
Cyclophosphamide
Follicular Lymphoma (FL)
Odronextamab
Diffuse Large B-cell Lymphoma (DLBCL)
Intravitreal aflibercept injection [IAI]
Nonproliferative Diabetic Retinopathy
REGN5713
Allergic Rhinitis
Indomethacin
Acute Gout Flare
aflibercept
Diabetic Macular Edema
BNT116
Advanced Non-Small Cell Lung Cancer
REGN5458
Multiple Myeloma
Tirzepatide
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Intravitreal Aflibercept Injection (IAI)
Neovascular Age-Related Macular Degeneration
ALN-ANG3
Diabetic Kidney Disease (DKD)
High-dose aflibercept
Neovascular (Wet) Age-Related Macular Degeneration
REGN5678
Metastatic Castration-resistant Prostate Cancer
Enoxaparin
Venous Thromboembolism
REGN7075
Advanced Solid Tumors
REGN7041
Active Noninfectious Uveitis Affecting the Posterior Segment
REGN1908-1909
Cat Allergy
REGN5668
Ovarian Cancer
Platinum-based chemotherapy
Non-Small Cell Lung Cancer
REGN7544
Postural Orthostatic Tachycardia Syndrome (POTS)
VEGF Trap Eye
Macular Degeneration
REGN10933+REGN10987 combination therapy
COVID-19
REGN910-3
Diabetic Macular Edema
REGN7945+Linvoseltamab
Relapsed/Refractory Multiple Myeloma
Low-Dose REGN4461
Generalized Lipodystrophy
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Homozygous Familial Hypercholesterolemia
REGN10597
Melanoma
AR101
Peanut Allergy
REGN3918
Paroxysmal Nocturnal Hemoglobinuria (PNH)
ALN-CFB
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Olatorepatide
Overweight or Obesity
REGN2477
Fibrodysplasia Ossificans Progressiva
Timothy Grass SCIT
Allergic Rhinitis
casirivimab+imdevimab
Healthy
PB
Sepsis-Induced Hypotension
REGN5381
Heart Failure
REGV131
Hemophilia B
REGN7999
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
ISA101b
Cervical Cancer
Fixed Dose Combination (FDC) cemiplimab+fianlimab
Melanoma
REGN1033 (SAR391786)
Sarcopenia
Vonsetamig
Chronic Kidney Disease (CKD)
REGN5093
NSCLC
Intravitreal Aflibercept Injection
Diabetic Macular Edema
Ubamatamab
Ovarian Cancer
REGN5459
Relapsed Multiple Myeloma
ALN-SOD
Amyotrophic Lateral Sclerosis (ALS)
REGN13335
Pulmonary Arterial Hypertension (PAH)
Trevogrumab-Part A
Obesity
Tocilizumab
Recurrent Ovarian Cancer
ALN-HSD
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Platinum Doublet
Non-small Cell Lung Cancer
REGN17372+Linvoseltamab
Relapsed Refractory Multiple Myeloma (RRMM)
ALN-CIDEB
Metabolic Dysfunction-Associated Steatotic Liver Disease
ALN-PNP
Healthy Volunteers
FDC fianlimab+cemiplimab
Head and Neck Squamous Cell Carcinoma (HNSCC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Dupixent Dupilumab | Approved | Atopic Dermatitis | - | - |
aflibercept 8 mg PFS | Phase 3 | Diabetic Macular Edema (DME) | - | - |
Cemdisiran | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Investigator Choice (IC) Chemotherapy | Phase 3 | Squamous Cell Carcinoma (SCC) | - | - |
Rilonacept | Phase 3 | Gout | - | - |
Suptavumab 30 mg/kg | Phase 3 | Respiratory Syncytial Virus Infections | - | - |
cemiplimab | Phase 3 | Advanced Cutaneous Squamous Cell Carcinoma | - | - |
Elotuzumab | Phase 3 | Relapsed Refractory Multiple Myeloma (RRMM) | - | - |
Garetosmab | Phase 3 | Fibrodysplasia Ossificans Progressiva | - | - |
Statin | Phase 3 | Hypercholesterolemia | - | - |
Fasinumab | Phase 3 | Osteoarthritis of the Knee or Hip | - | - |
REGN5715 | Phase 3 | Allergic Conjunctivitis | - | - |
Lenalidomide | Phase 3 | Relapsed/Refractory Follicular Lymphoma | - | - |
Pembrolizumab | Phase 3 | Melanoma | - | - |
Evinacumab | Phase 3 | Hypercholesterolemia | - | - |
Linvoseltamab | Phase 3 | Monoclonal Gammopathy of Undetermined Significance (MGUS) | - | - |
Atorvastatin | Phase 3 | Hypercholesterolemia | - | - |
Naproxen | Phase 3 | Osteoarthritis, Knee | - | - |
Doxorubicin | Phase 3 | Follicular Lymphoma (FL) | - | - |
Carfilzomib | Phase 3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | - | - |
Ravulizumab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Fianlimab | Phase 3 | Melanoma | - | - |
rilonacept 160 mg | Phase 3 | Familial Cold Autoinflammatory Syndrome (FCAS) | - | - |
REGN5714 | Phase 3 | Allergic Rhinitis | - | - |
VEGF Trap-Eye 2.0mg | Phase 3 | Macular Edema Secondary to Central Retinal Vein Occlusion | - | - |
Daratumumab | Phase 3 | High Risk Smoldering Multiple Myeloma (HR-SMM) | - | - |
Pozelimab + Cemdisiran | Phase 3 | Generalized Myasthenia Gravis | - | - |
Pozelimab | Phase 3 | CD55-deficient Protein-losing Enteropathy | - | - |
ranibizumab | Phase 3 | Macular Degeneration | - | - |
Pemetrexed | Phase 3 | Non-small Cell Lung Cancer | - | - |
mibavademab | Phase 3 | Generalized Lipodystrophy | - | - |
REGN9933 | Phase 3 | Venous Thromboembolism | - | - |
Oral corticosteroids (OCS) | Phase 3 | Bullous Pemphigoid | - | - |
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) | Phase 3 | Diabetic Macular Edema | - | - |
REGN1908 | Phase 3 | Allergic Conjunctivitis | - | - |
Rosuvastatin | Phase 3 | Hypercholesterolemia | - | - |
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | Phase 3 | Branch Retinal Vein Occlusion | - | - |
Acetylsalicylic Acid (ASA) | Phase 3 | Symptomatic Venous Thromboembolism (VTE) | - | - |
Rilonacept 80 mg | Phase 3 | Intercritical Gout | - | - |
Aflibercept 8 mg | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Phase 3 | Macular Degeneration | - | - |
REGN7508 | Phase 3 | Venous Thromboembolism (VTE) | - | - |
Libtayo Cemiplimab | Phase 3 | Non-Small Cell Lung Cancer | Fast Track | - |
Alirocumab | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
Intravitreal Aflibercept Injection 2mg | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
Rivaroxaban | Phase 3 | Peripheral Artery Disease (PAD) | - | - |
Apixaban | Phase 3 | Atrial Fibrillation (AF) | - | - |
Sarilumab | Phase 3 | COVID-19 | - | - |
Ezetimibe | Phase 3 | Hypercholesterolemia | - | - |
REGN475 | Phase 3 | Sciatica | - | - |
REGN2810 | Phase 3 | Non-small Cell Lung Cancer | - | - |
Carboplatin | Phase 3 | Resectable Non-small Cell Lung Cancer | - | - |
REGN10933 + REGN10987 | Phase 3 | Healthy Participants | - | - |
Gemcitabine | Phase 3 | Carcinoma，Non-Small-Cell Lung | - | - |
LMT (atorvastatin, simvastatin, or rosuvastatin) | Phase 3 | Heterozygous Familial Hypercholesterolemia | - | - |
Dexamethasone | Phase 3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | - | - |
Dupilumab | Phase 3 | Atopic Dermatitis (AD) | - | - |
Cyclophosphamide | Phase 3 | Follicular Lymphoma (FL) | - | - |
Odronextamab | Phase 3 | Diffuse Large B-cell Lymphoma (DLBCL) | - | - |
Intravitreal aflibercept injection [IAI] | Phase 3 | Nonproliferative Diabetic Retinopathy | - | - |
REGN5713 | Phase 3 | Allergic Rhinitis | - | - |
Indomethacin | Phase 3 | Acute Gout Flare | - | - |
aflibercept | Phase 3 | Diabetic Macular Edema | - | - |
BNT116 | Phase 2 | Advanced Non-Small Cell Lung Cancer | - | - |
REGN5458 | Phase 2 | Multiple Myeloma | OrphanFast TrackBreakthrough | - |
Tirzepatide | Phase 2 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | - | - |
Intravitreal Aflibercept Injection (IAI) | Phase 2 | Neovascular Age-Related Macular Degeneration | - | - |
ALN-ANG3 | Phase 2 | Diabetic Kidney Disease (DKD) | - | - |
High-dose aflibercept | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration | - | - |
REGN5678 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
Enoxaparin | Phase 2 | Venous Thromboembolism | - | - |
REGN7075 | Phase 2 | Advanced Solid Tumors | - | - |
REGN7041 | Phase 2 | Active Noninfectious Uveitis Affecting the Posterior Segment | - | - |
REGN1908-1909 | Phase 2 | Cat Allergy | - | - |
REGN5668 | Phase 2 | Ovarian Cancer | - | - |
Platinum-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
REGN7544 | Phase 2 | Postural Orthostatic Tachycardia Syndrome (POTS) | - | - |
VEGF Trap Eye | Phase 2 | Macular Degeneration | - | - |
REGN10933+REGN10987 combination therapy | Phase 2 | COVID-19 | - | - |
REGN910-3 | Phase 2 | Diabetic Macular Edema | - | - |
REGN7945+Linvoseltamab | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Low-Dose REGN4461 | Phase 2 | Generalized Lipodystrophy | - | - |
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC | Phase 2 | Homozygous Familial Hypercholesterolemia | - | - |
REGN10597 | Phase 2 | Melanoma | - | - |
AR101 | Phase 2 | Peanut Allergy | - | - |
REGN3918 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
ALN-CFB | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
Olatorepatide | Phase 2 | Overweight or Obesity | - | - |
REGN2477 | Phase 2 | Fibrodysplasia Ossificans Progressiva | - | - |
Timothy Grass SCIT | Phase 2 | Allergic Rhinitis | - | - |
casirivimab+imdevimab | Phase 2 | Healthy | - | - |
PB | Phase 2 | Sepsis-Induced Hypotension | - | - |
REGN5381 | Phase 2 | Heart Failure | - | - |
REGV131 | Phase 2 | Hemophilia B | - | - |
REGN7999 | Phase 2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | - | - |
ISA101b | Phase 2 | Cervical Cancer | - | - |
Fixed Dose Combination (FDC) cemiplimab+fianlimab | Phase 2 | Melanoma | - | - |
REGN1033 (SAR391786) | Phase 2 | Sarcopenia | - | - |
Vonsetamig | Phase 2 | Chronic Kidney Disease (CKD) | - | - |
REGN5093 | Phase 2 | NSCLC | - | - |
Intravitreal Aflibercept Injection | Phase 2 | Diabetic Macular Edema | - | - |
Ubamatamab | Phase 2 | Ovarian Cancer | - | - |
REGN5459 | Phase 2 | Relapsed Multiple Myeloma | - | - |
ALN-SOD | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
REGN13335 | Phase 2 | Pulmonary Arterial Hypertension (PAH) | - | - |
Trevogrumab-Part A | Phase 2 | Obesity | - | - |
Tocilizumab | Phase 2 | Recurrent Ovarian Cancer | - | - |
ALN-HSD | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | - | - |
Platinum Doublet | Phase 2 | Non-small Cell Lung Cancer | - | - |
REGN17372+Linvoseltamab | Phase 2 | Relapsed Refractory Multiple Myeloma (RRMM) | - | - |
ALN-CIDEB | Phase 2 | Metabolic Dysfunction-Associated Steatotic Liver Disease | - | - |
ALN-PNP | Phase 2 | Healthy Volunteers | - | - |
FDC fianlimab+cemiplimab | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | - | - |
Atopic Dermatitis
1 drug in this indication
Non-Small Cell Lung Cancer
1 drug in this indication
Multiple Myeloma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Regeneron Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 113 drug candidates in Regeneron Pharmaceuticals, Inc.'s (REGN) pipeline across Phase 3, Phase 2, Approved. Its lead program is aflibercept 8 mg PFS (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Regeneron Pharmaceuticals, Inc.'s next FDA catalyst?→
Regeneron Pharmaceuticals, Inc.'s (REGN) next tracked catalyst is a Data Readout expected July 21, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track REGN biotech catalysts?→
Add REGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Regeneron Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.